{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-040608","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.239823+00:00","generated_at":"2026-06-04T06:15:53.086606+00:00","sec_items":["3.03","5.03","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NRx Pharmaceuticals to effect 1-for-10 reverse stock split effective April 1, 2024 to maintain Nasdaq listing","bullets":["Reverse stock split at 1:10 ratio; shares outstanding reduced from ~95.7M to ~9.57M.","Effective at 4:30 p.m. ET on April 1, 2024; trading on split-adjusted basis begins April 2, 2024 under symbol NRXP.","Fractional shares rounded up to nearest whole share; par value unchanged.","Chairman cites upcoming clinical trial readouts, planned NDA filing, and dividend of HOPE Therapeutics shares.","CUSIP changes to 629444209; stockholders need not exchange certificates."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-040608","json":"https://secwatch.observer/filing/0001104659-24-040608.json","markdown":"https://secwatch.observer/filing/0001104659-24-040608.md","text":"https://secwatch.observer/filing/0001104659-24-040608.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000110465924040608/0001104659-24-040608-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000110465924040608/tm2410082d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:15:53.086606+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ee4fc5cd7d6f5c64578b83160c2ea4d4b20f9cdf","claim":"NRX Pharmaceuticals, Inc.: Amendment to certificate of incorporation to effect a 1-for-10 reverse stock split of common stock, effective April 1, 2024 (effective 2024-04-01).","evidence_excerpt":"On March 28, 2024, NRx Pharmaceuticals, Inc. (the “ Company ”) announced that it had filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Second Amended and Restated Certificate of Incorporation (the “ Charter Amendment ”) to effect a 1-for-10 reverse stock split (the “ Reverse Stock Split ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), effective as of 4:30 p.m. Eastern Standard Time on April 1, 2024 (the “ Effective Time ”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000110465924040608/0001104659-24-040608-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-04-01"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}